{"listing":{"listing_type":"company","name":"Altay Therapeutics","slug":"altay-therapeutics","tagline":"Altay develops disease-modifying therapies targeting transcription…","description":"Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer.  Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. \n\nWith a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. \n\nWe know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. \n\nWith our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.\n\nAltay Therapeutics is a Y Combinator company (Winter 2020). YC-listed status: Active.","url":"https://www.altaytherapeutics.com/","is_stealth":false,"normalized_domain":"altaytherapeutics.com","normalized_url_key":"altaytherapeutics.com","parent_slug":null,"parent":null,"type_data":{},"logo":null,"links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/altay-therapeutics","platform":"ycombinator"}],"entry_points":[{"kind":"homepage","url":"https://www.altaytherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true}],"primary_entry_points":{"human":{"kind":"homepage","url":"https://www.altaytherapeutics.com/","audience":"any","primary":false,"listed_by":"community","derived_from":"url","on_listing_domain":true},"agent":null},"founders":[],"media":null,"categories":["Healthcare","Therapeutics","AI-powered Drug Discovery","Biotech","Drug discovery"],"stage":null,"founded_year":null,"location":"San Francisco, CA, USA; South San Francisco, CA, USA","pricing":null,"twitter":null,"github":null,"linkedin":null,"contact_email":null,"added_at":"2026-09-03T06:29:27.996Z","added_via":"web","geo":{"keywords":["Y Combinator","YC Winter 2020","AI-powered Drug Discovery","Biotech","Therapeutics","Drug discovery"],"one_liner_for_search":"Altay Therapeutics — Altay develops disease-modifying therapies targeting transcription… (Y Combinator Winter 2020)","canonical_facts":["Y Combinator batch: Winter 2020","YC company status: Active","Team size (per YC directory): 6","YC industry: Healthcare","YC subindustry: Healthcare / Therapeutics","Former names: Altay Therapeutics Inc","Regions (per YC): United States of America, America / Canada"]},"agents":null,"featured_until":null,"example":false,"ownership_status":"unclaimed","claimed_by_agent_id":null,"claimed_via_claim_id":null,"claimed_at":null,"updated_at":"2026-09-03T06:29:27.996Z","is_featured":false,"category_memberships":[{"kind":"industry","slug":"ai-powered-drug-discovery","name":"AI-powered Drug Discovery","note":null,"profile_url":"/industries/ai-powered-drug-discovery"},{"kind":"industry","slug":"biotech","name":"BioTech","note":null,"profile_url":"/industries/biotech"},{"kind":"industry","slug":"drug-discovery","name":"Drug discovery","note":null,"profile_url":"/industries/drug-discovery"},{"kind":"industry","slug":"healthcare","name":"Healthcare","note":null,"profile_url":"/industries/healthcare"},{"kind":"industry","slug":"therapeutics","name":"Therapeutics","note":null,"profile_url":"/industries/therapeutics"}]}}